Prevalence and Pathogenesis of Barrett's Esophagus in Luoyang, China

Asian Pacific Journal of Cancer Prevention

Volumn 13, Issue 5, 2012, Pages 2185-2191

  Zhang, Ru Gang ^a,b   Wang, Chang Song ^b   Gao, Cun Fang ^b  

^a CHINESE PLA GENERAL HOSPITAL   (China)

^b Southwest Hospital   (China)

Author keywords

Barrett's esophagus; Luoyang, China; Pathogenesis; Prevalence

Indexed keywords

CASPASE 3; HEAT SHOCK PROTEIN 110; HEAT SHOCK PROTEIN 70; HEAT SHOCK PROTEIN 90; HSP90ALPHA PROTEIN, HUMAN; HSPH1 PROTEIN, HUMAN; TELOMERASE; TERT PROTEIN, HUMAN; TUMOR MARKER;

ADENOCARCINOMA; ARTICLE; BARRETT ESOPHAGUS; CANCER STAGING; CHINA; COMPARATIVE STUDY; ENZYME IMMUNOASSAY; ESOPHAGITIS; FEMALE; FOLLOW UP; HUMAN; MALE; METABOLISM; METAPLASIA; MIDDLE AGED; PATHOLOGY; PREVALENCE; PROGNOSIS; PROSPECTIVE STUDY;

ADENOCARCINOMA; BARRETT ESOPHAGUS; CASPASE 3; CHINA; ESOPHAGITIS; FEMALE; FOLLOW-UP STUDIES; HSP110 HEAT-SHOCK PROTEINS; HSP70 HEAT-SHOCK PROTEINS; HSP90 HEAT-SHOCK PROTEINS; HUMANS; IMMUNOENZYME TECHNIQUES; MALE; METAPLASIA; MIDDLE AGED; NEOPLASM STAGING; PREVALENCE; PROGNOSIS; PROSPECTIVE STUDIES; TELOMERASE; TUMOR MARKERS, BIOLOGICAL;

EID: 84872686387     PISSN: 15137368     EISSN: 2476762X     Source Type: Journal    
DOI: 10.7314/APJCP.2012.13.5.2185     Document Type: Article

References (36)

1. Aldulaimi DM, Cox M, Nwokolo CU, Loft DE (2005). Barrett's surveillance is worthwhile and detects curable cancers. A prospective cohort study addressing cancer incidence, treatment outcome and survival. Eur J Gastroenterol Hepatol, Sep, 17, 943-50.
2. Al Madi MA (2009). Barrett's esophagus: where do we stand? Saudi J Gastroenterol, 15, 2-10.
3. Burnat G, Majka J, Konturek PC (2010). Bile acids are multifunctional modulators of the Barrett's carcinogenesis. J Physiol Pharmacol, 61, 185-92.
4. Candé C, Cohen I, Daugas E et al (2002). Apoptosis-inducing factor(AIF): a novel caspase independent death effector released from mitochondria. Biochimie, 84, 215-22.
5. Casson AG, Williams L, Guernsey DL (2005). Epidemiology and molecular biology of Barrett esophagus. Semin Thorac Cardiovasc Surg, 17, 284-291.
6. Chen Xue-mei, ZOU Fei (2006). Stress response changes of NIH-3T3 cells with HSP90a expression inhibition by RNA interference. J South Med Univ, 26, 1118-20.
7. Ciriza-de-los-Ríos C. Barrett s esophagus - a review. Rev Esp Enferm Dig, 102, 257-69.
8. Clément G, Braunschweig R, Pasquier N et al (2006). Methylation of APC, TIMP3, and TERT: a new predictive marker to distinguish Barrett's oesophagus patients at risk for malignant transformation. J Pathol, 208, 100-7.
9. Didelot C, Schmitt E, Brunet M et al (2006). Heat shock proteins: endogenous modulators of apoptotic cell death. Handb Exp Pharmacol, 171-98.
10. Doak SH, Jenkins GJ, Parry EM (2004). Differential expression of the MAD2, BUB1 and HSP27 genes in Barrett's oesophagus-their association with aneuploidy and neoplastic progression. Mutat Res, 547, 133-44.
11. Dzaman-Serafin S, Telatynska-Mieszek B, Ciechanowski K (2005). Heat shock proteins and their characteristics. Pol Merkur Lekarski, 19, 215-9.
12. Fouad YM, Makhlouf MM, Tawfik HM(2009). Barrett's esophagus: prevalence and risk factors in patients with chronic GERD in Upper Egypt. World J Gastroenterol, 15, 3511-15.
13. Gertler R, Doll D, Maak M, Feith M, Rosenberg R (2008). Telomere length and telomerase subunits as diagnostic and prognostic biomarkers in Barrett carcinoma. Cancer, 112, 2173-80.
14. Glickman JN, Chen YY, Wang HH, Antonioli DA, Odze RD (2001). Phenotypic characteristics of a distinctive multilayered epithelium suggests that it is a precursor in the development of Barrett's esophagus. Am J Surg Pathol, 25, 569-78.
15. Ishihara K, Yamagishi N, Saito Y et al (2003). Hsp105 alpha suppresses the aggregation of truncated androgen receptor with expanded CAG repeats and cell toxicity. J Biol Chem, 278, 25143-50.
16. Jones TF, Sharma P, Daaboul B (2002). Yield of intestinal metaplasia in patients with suspected short-segment Barrett's esophagus (SSBE) on repeat endoscopy. Dig Dis Sci, 47, 2108-11.
17. Kim JH, Rhee PL, Lee JH (2007). Prevalence and risk factors of Barrett's esophagus in Korea. J Gastroenterol Hepatol, 22, 908-12.
18. Lavrik IN, Golks A, Krammer PH (2002). Caspases: pharmacological manipulation of cell death. J Clin Invest, 115, 2665-72.
19. Maser RS, DePinho RA (2002). Connecting chromosomes, crisis, and cancer. Science, 297, 565-9.
20. Modiano N, Gerson LB (2007). Barrett's esophagus: Incidence, etiology, pathophysiology, prevention and treatment. Ther Clin Risk Manag, 3, 1035-145.
21. Neckers L (2007). Heat shock protein 90: the cancer chaperone. J Biosci, 32, 517-30.
22. Ostrowski J, Mikula M, Karczmarski J (2007). Molecular defense mechanisms of Barrett's metaplasia estimated by an integrative genomics. J Mol Med, 85, 733-43.
23. Pandey P, Saleh A, Nakazawa A (2000). Negative regulation of cytochrome c-mediated oligomerization of Apaf-1 and activation of procaspase-9 by heat shock protein 90. EMBO J, 19, 4310-22.
24. Parenti A, Leo G, Porzionato A (2006). Expression of survivin, p53, and caspase 3 in Barrett's esophagus carcinogenesis. Hum Pathol, 37, 16-22.
25. Paull A, Trier JS, Dalton MD (1976). The histologic spectrum of Barrett's esophagus. N Engl J Med, 295, 476-80.
26. Sarosi G, Brown G, Jaiswal K (2008). Bone marrow progenitor cells contribute to esophageal regeneration and metaplasia in a rat model of Barrett's esophagus. Dis Esophagus, 21, 43-50.
27. Sawhney RA, Shields HM, Allan CH (1996). Morphological characterization of the squamocolumnar junction of the esophagus in patients with and without Barrett's epithelium. Dig Dis Sci, 41, 1088-98.
28. Sharma P, Dent J, Armstrong D (2006). The development and validation of an endoscopic grading system for Barrett's esophagus: the Prague C & M criteria. Gastroenterology, 131, 1392-9.
29. Smith CM, Watson DI, Michael MZ, Hussey DJ (2010). MicroRNAs, development of Barrett's esophagus, and progression to esophageal adenocarcinoma. World J Gastroenterol, 16, 531-7.
30. Soldes OS, Kuick RD, Thompson IA 2nd, et al (1999). Differential expression of Hsp27 in normal oesophagus, Barrett's metaplasia and oesophageal adenocarcinomas. Br J Cancer, 79, 595-603.
31. Sollano JD, Wong SN, Andal-Gamutan T (2007). Erosive esophagitis in the Philippines: a comparison between two time periods. J Gastroenterol Hepatol, 22, 1650-5.
32. Souza RF. Biomarkers in Barrett's Esophagus (2010). Tech Gastrointest Endosc, 12, 116-1212.
33. van Kerkhoven LA, van Rijswijck SJ, van Rossum LG (2007). Open-access upper gastrointestinal endoscopy a decade after the introduction of proton pump inhibitors and helicobacter pylori eradication: a shift in endoscopic findings. Digestion, 75, 227-31.
34. Wang KK, Sampliner RE (2008). Updated guidelines 2008 for the diagnosis, surveillance and therapy of Barrett's esophagus. Am J Gastroenterol, 103, 788-97.
35. Wang W, Zhang ZJ, Lin KR, et al (2006). The prevalence, clinical and endoscopic characteristics of Barrett esophagus in Fujian. Chin J Intern Med, 45, 393-5 (in Chinese).
36. Zhang J, Zhang S, Luo J, et al (2001). Barrett' s esophagus: clinical study. Chin J Dig Endosc, 18, 15-8 (in Chinese).